N/A N=62 Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery
Chronic Sinusitis
Primary: Pain Level Assessed Using a Visual Analogue Scale (VAS) Scale — 0; 0; 0; 2 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,072 Cardiovascular Disease Risk Factors in Chinese American Immigrants
Hypertension · Cardiovascular Diseases · Diabetes Mellitus
Primary: Number of Participants With Hypertension — 532 participants
Phase 2 N=143 Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infection
Primary: Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit — 39; 41; 24; 3 participants
N/A N=3,109 Toviaz Post Marketing Surveillance Study
Overactive Bladder
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 8.53 Percentage of Participants
Phase 3 N=600 Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)
Lymphoma · Infection · Leukemia
Primary: Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant — 74.9; 78.2…
Phase 3 N=1,438 Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
Essential Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg — -20.48; -18.15 mmHg — p=<0.001
Phase 3 N=44 Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
Central Precocious Puberty
Primary: Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6 — 93.18 percentage of…
Phase 3 N=57 Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
Diabetes Mellitus, Type 2
Primary: Time to 99% Inhibition of Serum Thromboxane — 26.71; 64.57 hours
Phase 3 N=40 Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
Diabetes Mellitus, Type 2
Primary: Time to 99% Inhibition of Serum Thromboxane (TxB2) — 12.36; 16.65; 48.64 Hours
Phase 1 N=80 First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 1 — 0; 0; 0; 0 participants
Phase 2 N=459 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (Double Blind Phase) — -9.76; -18.73; -16.19; -18.25 Units on a scale — p=0.2846
N/A N=105 Pancreatic Juice Diagnosis From Duodenum
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Phase 3 N=854 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Lymphoma
Primary: Failure-free Survival at 5 Years — 0.74; 0.71 Proportion of patients — p=0.32
Phase 4 N=228 A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
Colorectal Cancer
Primary: Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE — 56.1; 6.1; 0.4 percentage of participants
Phase 2 N=17 Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Recurrent Bladder Cancer · Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria — 0 participants